Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)
A Study to Evaluate the Pharmacokinetics of Adalimumab in Combination With Methotrexate for the Treatment of Patients With Ulcerative Colitis
Sponsor: Abbott
Terminated
Unable to achieve recruitment target.
Other terminated trials from Abbott
Other Ulcerative Colitis trials with similar outcome
This PHASE2 trial investigates Ulcerative Colitis and is currently terminated or withdrawn. Abbott leads this study, which shows 12 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Sep 2021 — Dec 2022 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated · Phase: PHASE4 → PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Unknown Status PHASE4
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
-
Nov 2018 — Nov 2020 [monthly]
Active Not Recruiting PHASE4
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE4
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
Status: Enrolling By Invitation → Active Not Recruiting
-
Apr 2017 — Dec 2017 [monthly]
Enrolling By Invitation PHASE4
-
Jan 2017 — Apr 2017 [monthly]
Enrolling By Invitation PHASE4
First recorded
Jun 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott
- Alimentiv Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.